PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
43.89%
Revenue growth above 1.5x AR's 0.59%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
30.11%
Positive gross profit growth while AR is negative. John Neff would see a clear operational edge over the competitor.
108.64%
EBIT growth below 50% of AR's 7292.14%. Michael Burry would suspect deeper competitive or cost structure issues.
108.64%
Operating income growth under 50% of AR's 7292.14%. Michael Burry would be concerned about deeper cost or sales issues.
935.79%
Net income growth above 1.5x AR's 582.23%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
104.86%
EPS growth under 50% of AR's 587.50%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
104.86%
Diluted EPS growth under 50% of AR's 587.50%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.01%
Share reduction more than 1.5x AR's 0.12%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.01%
Diluted share count expanding well above AR's 0.01%. Michael Burry would fear significant dilution to existing owners' stakes.
1.99%
Dividend growth of 1.99% while AR is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-9.26%
Negative OCF growth while AR is at 34.42%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-52.66%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
15.95%
10Y revenue/share CAGR under 50% of AR's 544.65%. Michael Burry would suspect a lasting competitive disadvantage.
-40.32%
Negative 5Y CAGR while AR stands at 544.65%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-3.52%
Negative 3Y CAGR while AR stands at 544.65%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-17.95%
Negative 10Y OCF/share CAGR while AR stands at 363.36%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-73.84%
Negative 5Y OCF/share CAGR while AR is at 363.36%. Joel Greenblatt would question the firm’s operational model or cost structure.
-48.28%
Negative 3Y OCF/share CAGR while AR stands at 363.36%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
790.84%
Net income/share CAGR above 1.5x AR's 258.52% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
11281.02%
5Y net income/share CAGR above 1.5x AR's 258.52%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
2224.02%
3Y net income/share CAGR above 1.5x AR's 258.52%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-1.96%
Negative equity/share CAGR over 10 years while AR stands at 121.54%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-61.43%
Negative 5Y equity/share growth while AR is at 121.54%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-43.08%
Negative 3Y equity/share growth while AR is at 121.54%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
41.88%
Dividend/share CAGR of 41.88% while AR is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-82.77%
Negative 5Y dividend/share CAGR while AR stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-65.53%
Negative near-term dividend growth while AR invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-0.08%
Firm’s AR is declining while AR shows 13.26%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-100.00%
Inventory is declining while AR stands at 60.29%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
13.95%
Asset growth at 75-90% of AR's 15.79%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
37.06%
BV/share growth above 1.5x AR's 6.35%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-1.84%
We’re deleveraging while AR stands at 22.76%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-11.85%
We cut SG&A while AR invests at 17.83%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.